NCT04907253CompletedPhase 2
Quercetin in Coronary Artery By-pass Surgery
Étude randomisée contrôlée Par Placebo de Phase II Visant à Mesurer l'Effet Anti-inflammatoire et Anti-sénescence de la quercétine Lors d'Une Chirurgie Cardiaque
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 12 May 2021
- Start date
- 4 Jun 2021
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Montreal Heart Institute
- Diseases
- Coronary artery disease
- NCT number
- NCT04907253
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 100
- From 4 Jun 2021 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- have a cardiac surgery concomitant to the cardiac surgery of revascularization;
Other illness
- have an infection in the last 30 days;
- to have a past history of breast cancer or other tumors estrogen-dependent;
Lab values
- to have renal insufficiency (GFR less than 30);
- to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
Other
- to be in a stable state without MI in the last 30 days;
- to have a known cirrhosis;
- to be intolerant to flavonoids, niacine or ascorbic acid;
- take quinolone;
- need for a quinolone during post-op;
- not being able to give a free and enlighten consent;
- not being able to speak French of English;
- take quercetin as a supplement.
Who the study is looking for
- to be able to speak French or English;
- to be able to give free and enlighten consent;
- be hospitalized and waiting for a cardiac surgery of revascularization;
- to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montreal Heart Institute Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
Related publications
- Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients.Aging Cell · 2025 · PMID 40375481
- Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery.Front Cardiovasc Med · 2021 · PMID 34746258
This page is information, not medical advice. Discuss any trial with your doctor.